AKT1 and triple-negative breast carcinoma: To explore the dominant AKT isoform for treatment of drug resistant triple negative breast cancer; we transduced the mouse triple negative breast cancer cell line, 4T1, with shRNA targeting AKT1/2/3 and subcutaneously implanted 1 × 106 cells into female Balb/c mice for investigating in vivo efficacy.